 After getting positive trial data, Novartis AG NYSE: NVS said it would in-license a new drug developing with Molecular Partners AG NASDAQ: MOLN to treat COVID-19. Novartis will pay CHF 150 million to in-license ensovibep from Molecular Partners. 